Literature DB >> 25144635

Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans.

Anne Nissen1, Mikkel Christensen, Filip K Knop, Tina Vilsbøll, Jens J Holst, Bolette Hartmann.   

Abstract

BACKGROUND: In humans, the pronounced postprandial reduction in bone resorption (decreasing bone resorption markers by around 50%) has been suggested to be caused by gut hormones. Glucose-dependent insulinotropic polypeptide (GIP) is a peptide hormone secreted postprandially from the small intestine. The hormone is known as an incretin hormone, but preclinical studies have suggested that it may also influence bone metabolism, showing both antiresorptive and anabolic effects as reflected by changes in biomechanical measures, microarchitecture, and activity of the bone cells in response to GIP stimulation. Its role in human bone homeostasis, however, is unknown.
OBJECTIVE: To examine the effect of GIP administration on bone resorption in humans.
MATERIALS AND METHODS: Plasma samples were obtained from 10 healthy subjects during four conditions: euglycemic (5 mmol/L) and hyperglycemic (12 mmol/L) 90-minute glucose clamps with co-infusion of GIP (4 pmol/kg/min for 15 min, followed by 2 pmol/kg/min for 45 min) or placebo. The samples were analyzed for concentrations of degradation products of C-terminal telopeptide of type I collagen (CTX), a bone resorption marker. RESULTS regarding effects on pancreatic hormone secretion have been published.
RESULTS: During euglycemia, the decremental area under the curve in CTX was significantly (P < .001) higher during GIP infusion (2084 ± 686 % × min) compared to saline infusion (656 ± 295 % × min). During hyperglycemia, GIP infusion significantly (P < .001) augmented the decremental area under the curve to 2785 ± 446 % × minutes, compared to 1308 ± 448 % × minutes during saline infusion, with CTX values corresponding to 49% of basal values.
CONCLUSIONS: We conclude that GIP reduces bone resorption in humans, interacting with a possible effect of hyperglycemia.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25144635     DOI: 10.1210/jc.2014-2547

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  26 in total

1.  GIP(3-30)NH2 is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study.

Authors:  Lærke S Gasbjerg; Mikkel B Christensen; Bolette Hartmann; Amalie R Lanng; Alexander H Sparre-Ulrich; Maria B N Gabe; Flemming Dela; Tina Vilsbøll; Jens J Holst; Mette M Rosenkilde; Filip K Knop
Journal:  Diabetologia       Date:  2017-09-25       Impact factor: 10.122

Review 2.  Update on the Acute Effects of Glucose, Insulin, and Incretins on Bone Turnover In Vivo.

Authors:  Vanessa D Sherk; Irene Schauer; Viral N Shah
Journal:  Curr Osteoporos Rep       Date:  2020-08       Impact factor: 5.096

3.  Effects of Biliopancreatic Diversion on Bone Turnover Markers and Association with Hormonal Factors in Patients with Severe Obesity.

Authors:  Anne-Frédérique Turcotte; Thomas Grenier-Larouche; Roth-Visal Ung; David Simonyan; Anne-Marie Carreau; André C Carpentier; Fabrice Mac-Way; Laetitia Michou; André Tchernof; Laurent Biertho; Stefane Lebel; Simon Marceau; Claudia Gagnon
Journal:  Obes Surg       Date:  2019-03       Impact factor: 4.129

4.  The Enteroendocrine System in Obesity.

Authors:  Emily L Miedzybrodzka; Frank Reimann; Fiona M Gribble
Journal:  Handb Exp Pharmacol       Date:  2022

5.  Effects of Gastric Bypass and Gastric Banding on Bone Remodeling in Obese Patients With Type 2 Diabetes.

Authors:  Elaine W Yu; Marlene Wewalka; Su-Ann Ding; Donald C Simonson; Kathleen Foster; Jens J Holst; Ashley Vernon; Allison B Goldfine; Florencia Halperin
Journal:  J Clin Endocrinol Metab       Date:  2015-11-24       Impact factor: 5.958

Review 6.  New perspectives on exploitation of incretin peptides for the treatment of diabetes and related disorders.

Authors:  Nigel Irwin; Peter R Flatt
Journal:  World J Diabetes       Date:  2015-11-10

7.  The effects of acute hyperinsulinemia on bone metabolism.

Authors:  Kaisa K Ivaska; Maikki K Heliövaara; Pertti Ebeling; Marco Bucci; Ville Huovinen; H Kalervo Väänänen; Pirjo Nuutila; Heikki A Koistinen
Journal:  Endocr Connect       Date:  2015-06-05       Impact factor: 3.335

Review 8.  Skeleton and glucose metabolism: a bone-pancreas loop.

Authors:  Maria Felicia Faienza; Vincenza Luce; Annamaria Ventura; Graziana Colaianni; Silvia Colucci; Luciano Cavallo; Maria Grano; Giacomina Brunetti
Journal:  Int J Endocrinol       Date:  2015-03-19       Impact factor: 3.257

9.  Effect of Intravenous Glucose Tolerance Test on Bone Turnover Markers in Adults with Normal Glucose Tolerance.

Authors:  Shou-Kui Xiang; Jing-Bo Wan; Xiao-Hong Jiang; Yong-Hua Zhu; Jin-Hong Ma; Fei Hua
Journal:  Med Sci Monit       Date:  2016-07-22

10.  N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor.

Authors:  L S Hansen; A H Sparre-Ulrich; M Christensen; F K Knop; B Hartmann; J J Holst; M M Rosenkilde
Journal:  Br J Pharmacol       Date:  2016-01-30       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.